|
The Journal of Lipid Research, Vol. 40, 1317-1327, July 1999
Copyright © 1999 by Lipid Research, Inc.
Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs
John R. Burnetta,
Lisa J. Wilcoxa,
Dawn E. Telforda,
Sandra J. Kleinstivera,
P. Hugh R. Barrettb,
Roger S. Newtonc, and
Murray W. Huffa
a Departments of Medicine and Biochemistry and The John P. Robarts Research Institute, University of Western Ontario, London, Ontario N6A 5K8, Canada
b Departments of Bioengineering and Medicine, University of Washington, Seattle, WA 98195
c Parke-Davis Pharmaceutical Research, Warner Lambert Co., Ann Arbor, MI 48105
Correspondence to:
Murray W. Huff
An orally bioavailable acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor, avasimibe (CI-1011), was used to test the hypothesis that inhibition of cholesterol esterification, in vivo, would reduce hepatic very low density (VLDL) apolipoprotein (apo) B secretion into plasma. ApoB kinetic studies were carried out in 10 control miniature pigs, and in 10 animals treated with avasimibe (10 mg/kg/d, n = 6; 25 mg/kg/d, n = 4). Pigs were fed a diet containing fat (34% of calories) and cholesterol (400 mg/d; 0.1%). Avasimibe decreased the plasma concentrations of total triglyceride, VLDL triglyceride, and VLDL cholesterol by 31;40% 3948%, and 31;35%, respectively. Significant reductions in plasma total cholesterol (35%) and low density lipoprotein (LDL) cholesterol (51%) concentrations were observed only with high dose avasimibe. Autologous 131I-labeled VLDL, 125I-labeled LDL, and [3H]leucine were injected simultaneously into each pig and apoB kinetic data were analyzed using multicompartmental analysis (SAAM II). Avasimibe decreased the VLDL apoB pool size by 40;43% and the hepatic secretion rate of VLDL apoB by 38;41%, but did not alter its fractional catabolism. Avasimibe decreased the LDL apoB pool size by 13;57%, largely due to a dose-dependent 25;63% in the LDL apoB production rate. Hepatic LDL receptor mRNA abundances were unchanged, consistent with a marginal decrease in LDL apoB FCRs. Hepatic ACAT activity was decreased by 51% (P = 0.050) and 68% (P = 0.087) by low and high dose avasimibe, respectively. The decrease in total apoB secretion correlated with the decrease in hepatic ACAT activity (r = 0.495; P = 0.026).
We conclude that inhibition of hepatic ACAT by avasimibe reduces both plasma VLDL and LDL apoB concentrations, primarily by decreasing apoB secretion.Burnett, J. R., L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. 1999. 40: 1317;1327.
Supplementary key words:
ACAT inhibitor, avasimibe, apolipoprotein B metabolism, kinetics, mRNA

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. E. Temel, L. Hou, L. L. Rudel, and G. S. Shelness
ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins
J. Lipid Res.,
July 1, 2007;
48(7):
1618 - 1627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Telford, B. G. Sutherland, J. Y. Edwards, J. D. Andrews, P. H. R. Barrett, and M. W. Huff
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
J. Lipid Res.,
March 1, 2007;
48(3):
699 - 708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Rochester and C. E. Cooke
The Changing Face of Dyslipidemia Therapies
Journal of Pharmacy Practice,
April 1, 2006;
19(2):
79 - 93.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Zern and M. L. Fernandez
Cardioprotective Effects of Dietary Polyphenols
J. Nutr.,
October 1, 2005;
135(10):
2291 - 2294.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Tardif, J. Gregoire, P. L. L'Allier, T. J. Anderson, O. Bertrand, F. Reeves, L. M. Title, F. Alfonso, E. Schampaert, A. Hassan, et al.
Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions
Circulation,
November 23, 2004;
110(21):
3372 - 3377.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Liang, P. Oelkers, C. Guo, P.-C. Chu, J. L. Dixon, H. N. Ginsberg, and S. L. Sturley
Overexpression of Human Diacylglycerol Acyltransferase 1, Acyl-CoA:Cholesterol Acyltransferase 1, or Acyl-CoA:Cholesterol Acyltransferase 2 Stimulates Secretion of Apolipoprotein B-containing Lipoproteins in McA-RH7777 Cells
J. Biol. Chem.,
October 22, 2004;
279(43):
44938 - 44944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Marcil, E. Delvin, C. Garofalo, and E. Levy
Butyrate Impairs Lipid Transport by Inhibiting Microsomal Triglyceride Transfer Protein in Caco-2 Cells
J. Nutr.,
July 1, 2003;
133(7):
2180 - 2183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Gupta and P. Khosla
Palmitic and Stearic Acids Similarly Affect Plasma Lipoprotein Metabolism in Cynomolgus Monkeys Fed Diets with Adequate Levels of Linoleic Acid
J. Nutr.,
August 1, 2001;
131(8):
2115 - 2120.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Wilcox, N. M. Borradaile, L. E. de Dreu, and M. W. Huff
Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP
J. Lipid Res.,
May 1, 2001;
42(5):
725 - 734.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
D. J. M. Delsing, E. H. Offerman, W. van Duyvenvoorde, H. van der Boom, E. C. M. de Wit, M. J. J. Gijbels, A. van der Laarse, J. W. Jukema, L. M. Havekes, and H. M. G. Princen
Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice
Circulation,
April 3, 2001;
103(13):
1778 - 1786.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff
The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs
Endocrinology,
November 1, 1999;
140(11):
5293 - 5302.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
D. K. Spady, M. N. Willard, and R. S. Meidell
Role of Acyl-Coenzyme A:Cholesterol Acyltransferase-1 in the Control of Hepatic Very Low Density Lipoprotein Secretion and Low Density Lipoprotein Receptor Expression in the Mouse and Hamster
J. Biol. Chem.,
August 25, 2000;
275(35):
27005 - 27012.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|